Telix Pharmaceuticals (TLX) Accumulated Expenses (2023 - 2024)

Telix Pharmaceuticals (TLX) has disclosed Accumulated Expenses for 2 consecutive years, with $31.2 million as the latest value for Q4 2024.

  • Quarterly Accumulated Expenses rose 26.58% to $31.2 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $31.2 million through Dec 2024, up 26.58% year-over-year, with the annual reading at $31.2 million for FY2024, 26.58% up from the prior year.
  • Accumulated Expenses for Q4 2024 was $31.2 million at Telix Pharmaceuticals, up from $24.7 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $31.2 million in Q4 2024, with the low at $24.7 million in Q4 2023.